AimedBio’s FGFR3 ADC, AMB302, Cleared by the U.S. FDA to Begin Phase 1 Clinical Trial

On November 1, 2024 AimedBio reported to have received IND clearance from the U.S. Food and Drug Administration (FDA) for AMB302.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

– AimedBio plans to initiate a Phase 1 clinical trial in both Korea and the United States, enrolling patients with solid tumors, including bladder cancer and head and neck cancer.

– First patient dosing is expected to begin in Q1 2025 in both countries.

(Press release, AimedBio, NOV 1, 2024, View Source;s_keyword=&s_where=&start=10 [SID1234656919])